Hu-Dan Pan

Hu-Dan Pan

Auto-generated profile, based on publicly available information

Hu-Dan Pan

State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in GigaScience
Verified
Journal Article
Open access
PDF file
HPHudan Pan
Hudan Pan
RGRuijin Guo
Ruijin Guo
JZJie Zhu
Jie Zhu
QWQi Wang
Qi Wang
YJYanmei Ju
Yanmei Ju
LLLiang Liu
Liang Liu
Background: Laboratory rats such as the Sprague-Dawley (SD) rats are an important model for biomedical studies in relation to human physiological or pathogenic processes. Here we report the first catalog of microbial genes in fecal samples from Sprague-Dawley rats. Findings: The catalog was established using 98 fecal samples from 49 SD rats, divided in 7 experimental groups, and collected at different time points 30 days apart. The established gene catalog comprises 5,130,167 non-redundant genes with an average length of 750 bp, among which 64.6% and 26.7% were annotated to phylum and genus levels, respectively. Functionally, 53.1%, 21.8%,and 31% of the genes could be annotated to KEGG orthologous groups, modules, and pathways, respectively. Conclusions: A comparison of rat gut metagenome catalogue with human or mouse revealed a higher pairwise overlap between rats and humans (2.47%) than between mice and humans (1.19%) at the gene level. Ninety-seven percent of the functional pathways in the human catalog were present in the rat catalogue, underscoring the potential use of rats for biomedical research.

1 April 2019 in Phytomedicine
Verified
Journal Article
Open access
RHRun-Yue Huang
Run-Yue Huang
HPHu-Dan Pan
Hu-Dan Pan
JWJia-Qi Wu
Jia-Qi Wu
HZHua Zhou
Hua Zhou
ZLZhan-Guo Li
Zhan-Guo Li
LLLiang Liu
Liang Liu
A combination of conventional disease-modifying anti-rheumatic drugs improves the treatment of rheumatoid arthritis but with high side-effects. Methotrexate (MTX) combination therapy that with high therapeutic efficacy and low toxicity is in demand in many countries to replace the use of expensive biological agents. This study was an open-label, 24-week, parallel randomized controlled trial conducted between November 2015 and December 2017. Patients were randomly assigned at a 3:2 ratio to receive MTX combined with sinomenine (SIN) at a dose of 120 mg twice daily, or leflunomide (LEF) at a dose of 20 mg once daily. Efficacy and safety were assessed at weeks 4, 12 and 24. The primary efficacy endpoint was the proportion of patients achieving an American College of Rheumatology (ACR)50 response and a European League Against Rheumatism (EULAR) good response at week 24. A total of 101/120 (84.2%) patients completed 24 weeks of observation. In the intention-to-treat (ITT) analysis, 65.3% of patients treated with MTX + SIN showed improved disease activity as determined by the ACR50 response at week 24 compared to 69.6% of patients treated with MTX + LEF. A similar insignificant pattern was found for the ACR20 and ACR70 responses, as well as the clinical disease activity index, EULAR response, and remission and low disease activity rates between these two treatment groups. The per-protocol analysis showed results consistent with those of the ITT analysis. Notably, significant reductions in gastrointestinal adverse reactions and liver toxicity were found in patients treated with MTX + SIN compared to patients treated with MTX + LEF (p < 0.05). Considering the balance of efficacy and toxicity, the current study provides evidence that MTX + SIN combination therapy is probably one of the choices for treating patients with active rheumatoid arthritis in addition to MTX + LEF combination therapy.

20 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
FHFanlei Hu
Fanlei Hu
XJXiang Jiang
Xiang Jiang
CGChunqing Guo
Chunqing Guo
YLYingni Li
Yingni Li
SCShixian Chen
Shixian Chen
ZLZhanguo Li
Zhanguo Li
Early diagnosis is critical to improve outcomes in rheumatoid arthritis (RA), but current diagnostic tools have limited sensitivity. Here we report a large-scale multicenter study involving training and validation cohorts of 3,262 participants. We show that serum levels of soluble scavenger receptor-A (sSR-A) are increased in patients with RA and correlate positively with clinical and immunological features of the disease. This discriminatory capacity of sSR-A is clinically valuable and complements the diagnosis for early stage and seronegative RA. sSR-A also has 15.97% prevalence in undifferentiated arthritis patients. Furthermore, administration of SR-A accelerates the onset of experimental arthritis in mice, whereas inhibition of SR-A ameliorates the disease pathogenesis. Together, these data identify sSR-A as a potential biomarker in diagnosis of RA, and targeting SR-A might be a therapeutic strategy.

1 November 2018 in Pharmacology & Therapeutics
Verified
Journal Article
Open access
Xing-Xing FanXing-Xing Fan
Xing-Xing Fan
HPHu-Dan Pan
Hu-Dan Pan
颖李颖 李
颖 李
RGRui-Jin Guo
Rui-Jin Guo
ELElaine Leung
Elaine Leung
LLLiang Liu
Liang Liu
Dysregulation of cell metabolism and redox balance is implicated in the pathogenesis and progression of cancer and autoimmune diseases. Because the cell proliferation and apoptotic regulatory pathways are interconnected with metabolic and redox signalling pathways, the current mono-target treatment is ineffective, and multi-drug resistance remains common. Complex diseases are often implicated in a network-based context of pathology; therefore, a new holistic intervention approach is required to block multi-crosstalk in such complicated circumstances. The use of therapeutic agents isolated from herbs to holistically modulate metabolism and redox state has been shown to relieve carcinoma growth and the inflammatory response in autoimmune disorders. Multiple clinically applied or novel herbal chemicals with metabolic and redox modulatory capacity as well as low toxicity have recently been identified. Moreover, new metabolic targets and mechanisms of drug action have been discovered, leading to the exploration of new pathways for drug repositioning, clinical biomarker spectra, clinical treatment strategies and drug development. Taken together with multiple supporting examples, the modulation of cell metabolism and the redox capacity using herbal chemicals is emerging as a new, alternative strategy for the holistic treatment of cancer and autoimmune disorders. In the future, the development of new diagnostic tools based on the detection of metabolic and redox biomarkers, reformulation of optimized herbal compositions using artificial intelligence, and the combination of herbs with mono-targeting drugs will reveal new potential for clinical application.

24 December 2024 in Phytomedicine
Verified
Journal Article
Closed access
RTRuimin Tian
Ruimin Tian
SGShan Guo
Shan Guo
SCShudong Chen
Shudong Chen
JWJiaqi Wu
Jiaqi Wu
ALAoyang Long
Aoyang Long
LLLiang Liu
Liang Liu

17 November 2025 in Phytomedicine
Verified
Journal Article
Open access
XCXiaodong Chen
Xiaodong Chen
JLJiangying Liu
Jiangying Liu
PLPeiying Lu
Peiying Lu
JZJiying Zhou
Jiying Zhou
LJLishuang Jiang
Lishuang Jiang
JWJiarui Wu
Jiarui Wu
Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative tool in biomedical research, overcoming the limitations of bulk RNA sequencing by resolving cellular heterogeneity, identifying rare cell subtypes, and reconstructing dynamic regulatory networks. This technology holds unprecedented potential for advancing Traditional Chinese Medicine (TCM) research, which faces challenges in deciphering the multi-component, multi-target mechanisms and heterogeneous syndromes using conventional methods. Relevant studies were retrieved from PubMed, Web of Science, Google Scholar, and CNKI up to June 2025. Search keywords included "single-cell RNA sequencing", "Traditional Chinese Medicine", "tumor", "inflammatory and autoimmune", and "cardiovascular, cerebrovascular". The inclusion criteria were as follows: (a) original research articles; (b) the application of scRNA-seq in TCM-related research, mainly for TCM in research related to tumors, inflammatory and autoimmune diseases, cardiovascular and cerebrovascular diseases, safety evaluation of TCM, and TCM Syndrome Research. The exclusion criteria comprised: (a) studies irrelevant to the review topic; (b) studies that utilized public datasets solely for data mining. scRNA-seq enables precise identification of bioactive targets of herbal compounds, dissection of synergistic modulation of cellular networks by TCM formulas, and construction of syndrome-associated molecular atlases. Its applications span diverse fields: unraveling immune regulation mechanisms of TCM in tumor therapy, elucidating immunomodulatory effects in inflammatory and autoimmune diseases, clarifying cardioprotective mechanisms in cardiovascular and cerebrovascular disorders, and facilitating safety evaluation of TCM. Additionally, scRNA-seq bridges TCM's holistic syndrome differentiation with molecular medicine by revealing dynamic correlations between TCM syndromes and cellular heterogeneity. By comparing with Western medical research paradigms, scRNA-seq highlights TCM's distinctive focus on network-driven regulation and holistic balance. This review summarizes cutting-edge studies and future directions, emphasizing scRNA-seq's role as a critical bridge in integrating TCM's systemic principles with molecular insights, thereby accelerating TCM and its integration into precision medicine.